Effect of Oral Enteral Nutrition in Pierre Robin Syndrome
NCT06303973 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2024-03-12
Summary
This was a randomized controlled study. The infants enrolled were randomly divided into the IOE group (with Intermittent Oro-Esophageal Tube Feeding, n=25) and the PNG group (with Nasogastric Tube Feeding, n=23), all receiving systemic therapy. Before and after 4-week treatment, pulmonary infection, swallowing function, nutritional status and body weight between the two group were compared.
Conditions
- Pierre Robin Syndrome
Interventions
- DEVICE
-
IOE
The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
- DEVICE
-
PNG
In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Sponsors & Collaborators
-
Muhammad
lead OTHER
Principal Investigators
-
Nieto Luis, Master · Site Coordinator of United Medical Group
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Month
- Max Age
- 12 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-10
- Primary Completion
- 2023-06-02
- Completion
- 2023-06-15
Countries
- Taiwan
Study Locations
More Related Trials
-
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
NCT02682381 ·Status: COMPLETED ·Phase: PHASE3
-
The Comparison of Different Administration Routes of Pediatric Premedication
NCT02313337 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
NCT05027308 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Teduglutide in Japanese Participants With Short Bowel Syndrome
NCT03663582 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support
NCT02980666 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
NCT00172185 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
NCT03571516 ·Status: COMPLETED ·Phase: PHASE3
-
Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT03197662 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of NASHA/Dx Gel for Fecal Incontinence
NCT00971269 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
NCT07319832 ·Status: RECRUITING
-
Amoxicillin for Enteral Nutrition Intolerance in Pediatric Intensive Care Unit
NCT05828758 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study in Infant With SBS
NCT02865122 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome
NCT05298085 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
NCT00798967 ·Status: COMPLETED ·Phase: PHASE3
-
Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea
NCT01814202 ·Status: COMPLETED ·Phase: NA
-
Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
NCT04733066 ·Status: UNKNOWN
-
Feeding Children Nasogastrically Versus Nasojejunally While Receiving Noninvasive Positive Pressure Ventilation
NCT01301352 ·Status: COMPLETED ·Phase: NA
-
Saline Enema Administration in Meconium Obstruction of Prematurity and Impact on the Resolution, Feeds, Microbiome, and Gut-brain Axis.
NCT06048614 ·Status: RECRUITING ·Phase: NA
-
An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004
NCT03596164 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility of Aerodigestive Stimulation Therapy Trial
NCT06118697 ·Status: RECRUITING ·Phase: NA
-
A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence
NCT00605826 ·Status: COMPLETED ·Phase: NA
-
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
NCT02629991 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
NCT03649477 ·Status: COMPLETED ·Phase: PHASE3
-
Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis
NCT01234883 ·Status: TERMINATED ·Phase: PHASE4
-
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
NCT00930644 ·Status: COMPLETED ·Phase: PHASE3